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Background: Knowledge on immunosuppressive factors in the pathogenesis of endometrial cancer is scarce. The
aim of this study was to assess Glycodelin (Gd) and its immunosuppressive isoform Glycodelin A (GdA) in
endometrial cancer tissue and to analyze its impact on clinical and pathological features and patient outcome.
Methods: 292 patients diagnosed and treated for endometrial cancer were included. Patient characteristics,
histology and follow-up data were available. Gd and GdA was determined by immunohistochemistry and in situ
hybridization was performed for Gd mRNA.
Results: Endometrial cancer shows intermediate (52.2%) or high (20.6%) expression for Gd in 72.8%, and GdA in
71.6% (intermediate 62.6%, high 9.0%) of all cases. The glycosylation dependent staining of GdA is tumour specific
and correlates with the peptide-specific Gd staining though neither of the two is associated with estrogen receptor,
progesterone receptor or clinic-pathological features. Also Gd protein positively correlates with Gd mRNA as quantified
by in situ hybridization. Gd positive cases have a favourable prognosis (p = 0.039), while GdA positive patients have a
poor outcome (p = 0.003). Cox-regression analysis proofed GdA to be an independent prognostic marker for patient
survival (p = 0.002), besides tumour stage, grade and the concomitant diagnosis of hypertension.
Conclusion: Gd and GdA are commonly expressed in endometrial cancer tissue and seem to be of relevance in
tumourigenesis. They differ not only in glycosylation but also in their biological activity, since only GdA holds
prognostic significance for a poor overall survival in endometrial cancer patients. This finding might be explained by
GdAs immunosuppressive capacity.
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Endometrial cancer is the fourth common carcinoma in
women following cancer of breast, colon and lung and
accounts for 5.6% of all malignancies [1]. The diagnosis
of endometrial cancer is typically made at postmeno-
pausal age [2] and its 5-year survival ranges between 75
and 83% [2].
Some risk factors for the development of endometrial
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reproduction in any medium, provided the ormechanisms in tumourigenesis are by far not explained.
A fast tumour progression is most likely favoured by
local immunosuppression, which decreases the body’s
own anti-tumour immunoreactivity. Until today little is
known about tumour induced, local immunosuppression
in endometrial cancer.
Glycodelin (Gd), also known progestagen-associated
endometrial protein, is a glycoprotein with immunosup-
pressive capacity, which is mainly produced in repro-
ductive tissue [9,10]. Four different isoforms have been
described: GdS (in seminal vesicles and seminal plasma)
[11], GdA (in endometrium/decidua, amniotic fluid, ma-
ternal serum) [12,13], GdF (in follicular fluid und ovi-
duct) [14] und GdC (in the cumulus oophorus) [15].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fer in glycosylation and biological activity [16,17].
GdA holds several immunosuppressive abilities, which
are best characterized in reproductive medicine [18]. These
include the suppression of lymphocyte proliferation and
inhibition of T- and B-cell activity [19-21]. Moreover, the
induction of apoptosis via GdA has been investigated [22].
Recently, we found GdA to be of prognostic signifi-
cance in ovarian cancer [23]. So far, there are very few
results on endometrial cancer cells and Gd or GdA [24]
and no clinical data on endometrial cancer. Therefore,
the aim of this study was to assess the expression of Gd
on mRNA and protein level. Further, we aimed to spe-
cify the proportion of the immunosuppressive glyko-
modification GdA in tissue samples of a large cohort of
endometrial cancer patients by using an extensively vali-
dated anti GdA antibody. Finally, we aimed to analyse
the impact of Gd/GdA positivity on clinical and patho-
logical features including patient outcome.
Methods
Patients
Formalin fixed paraffin embedded (FFPE) tissue of 292
endometrial cancer patients (Table 1) was available.
Most patients presented with early stage disease at pri-
mary diagnosis (Table 1). 72.6% of patients (n = 212)
showed a Type I carcinoma with endometrioid histology.
Among the remainder there were 7.9% with serous, 4.1%
with mucinous, 1.7% with clear cell histology and 0.3%
with squamous cell histology. 11.6% were classified as
mixed and 1.7% as undifferentiated carcinomas. Patients
were also evaluated for concomitant diseases and pre-
sented with hypertension in 39.7%, obesity in 30.5% and
diabetes in 11.3% of all patients.
Assay methods
Immunohistochemistry
Immunohistochemical (IHC) staining has been described
previously by us [23,26,27]. Glycosylation dependant
staining differences were assessed using the polyclonal
Gd and the monoclonal GdA antibody (A87-B/D2) [28].
Specificity of GdA binding was analyzed by Western blot
analysis [29-31]. This antibody is suitable for the detec-
tion of GdA in endometrial tumour tissues [26]. Our
former investigation showed that A87-B/D2 seems to be
less restricted to GdA carbohydrate structures than
other monoclonal antibodies made in our laboratories,
although none of the three monoclonal antibodies recog-
nize GdS or other pregnancy-related glycoproteins such as
hCG or transferrin isolated from amniotic fluid [26].
Formalin fixed paraffin embedded tissue sections were
dewaxed with xylol and endogenous peroxidase activity
was quenched by dipping in 3% hydrogen peroxide
(Merck, Darmstadt, Germany) in methanol for 20 min.Then sections were rehydrated in descending concentra-
tions of alcohol. For GdA staining epitope retrieval was
performed in a pressure cooker using sodium citrate
buffer (5 min, pH 6.0). Following PBS washes samples
were blocked as described in Table 2 and incubated with
the primary antibodies (Table 2). Then samples were fur-
ther processed as per manufacturer’s instructions. Finally,
immunoreactivity was visualized using diaminobenzidine
(Dako, Glostrup, Denmark), slides were counterstained
using haematoxylin, dehydrated in ascending concentra-
tions of alcohol, xylol treated and covered. Positive (pla-
centa tissue) and negative (species matched pre-immune
sera) controls were always included in the analysis
(Additional file 1).
Preparation of riboprobes
Preparation of riboprobes was performed as described
previously [27,33]. In short, a 227-bp fragment of the Gd
cDNA (positions +41 to +268) was cloned into the
EcoR1 restriction sites of pBluescript SK (Stratagene,
Amsterdam, The Netherlands) and labelled with digoxi-
genin (DIG) by in vitro transcription using the DIG RNA
labeling Kit (SP6/T7; Roche Biochemicals, Mannheim,
Germany). The antisense cRNA probe binds in situ to
Gd-mRNA and was utilized for Gd-mRNA detection. The
sense cRNA probe was used as negative control.
In situ hybridization
Non-radioactive in situ-hybridization (ISH) analysis of Gd
was performed on paraffin sections as described previ-
ously [27,28,34]. Briefly, paraffin sections were deparaf-
fined, rehydrated and permeabilized by pepsin digestion
(750 mg/ml pepsin in 0.2 M HCl, 37C, 30 min). Postfixa-
tion (paraformaldehyde 4%, 20 min, 4C) was followed by
acetylation using 0.25% acetic anhydride in triethanola-
mine (0.1 M, pH 8.0, 15 min). After dehydration in an as-
cending series of alcohol, the sections were hybridized for
16 hr (56°C) in a solution containing 50% formamide, 50%
solution D (4 M guanidine thiocyanate, 25 mM sodium
citrate, pH 7.0), 0.5% blocking reagent, 210 mg/ml t-RNA
derived from E. coli MRE 600, and 125 ng DIG-labeled
cRNA probe. After washing with decreased concentra-
tions of SSC (203 SSC: 3 M NaCl, 0.3 M sodium citrate,
pH 7.4), sections were incubated 1 hr with blocking re-
agent (all from Roche Biochemicals).
Bound riboprobe was visualized by incubation with alka-
line phosphatase-conjugated anti-DIG antibody (Roche




All tissue samples (n = 292) were gained at surgery in
patients who had been treated for primary endometrial
Table 1 Patient characteristics: Immunohistochemical
staining for oestrogen receptors (ER) (ER alpha, ER beta)
and progesterone receptors (PR) (PR-A and PR-B) were
performed and analysed as previously published by our
research group [25]
Grade (%) 1 147 (51.2)
(n = 287) 2 93 (32.4)
3 47 (16.4)
FIGO stage (%) I 219 (75.0)
(n = 292) II 21 (7.2)
III 44 (15.1)
IV 8 (2.7)
Histology (%) Endometrioid 212 (72.6)
(n = 292) Serous 23 (7.9)
Clear cell 5 (1.7)
Mucinous 12 (4.1)
Squamous cell 1 (0.3)
Mixed 34 (11.6)
Undifferentiated 5 (1.7)
Patient age ± sem [y]
(range)
65.1 ± 0.6 (35.6-88.1)
Deaths (%) 160 (54.8)
Survival ± sem [y] (95% CI) 13.6 ± 0.5 (12.6-14.6)
Follow up ± sem [y] (95% CI) 13.8 ± 0.3 (13.1-14.5)
Glycodelin (%) (n = 291) Low 79 (27.1)
Intermediate 152 (52.2)
High 60 (20.6)
Glycodelin A (%) (n = 289) Low 82 (28.4)
Intermediate 181 (62.6)
High 26 (9.0)
ER alpha (%) (n = 292) Positive 133 (45.5)
ER beta (%) (n = 292) Positive 40 (13.7)
PRA (%) (n = 292) Positive 121 (41.4)
PRB (%) (n = 292) Positive 134 (45.9)
Co-morbidities Hypertension (%) 116 (39.7)
Diabetes (%) 33 (11.3)
Obesity (%) 89 (30.5)
Lymphangiosis (%) (n = 292) Positive 27 (9.2)
Negative 263 (90.1)
Unknown 2 (0.7)
Hemangiosis (%) (n = 292) Positive 8 (2.7)
Negative 281 (96.2)
Unknown 3 (1.0)
Radiotherapy (%) (n = 292) Yes 116 (39.7)
No 170 (58.2)
Declined 6 (2.1)
Table 1 Patient characteristics: Immunohistochemical
staining for oestrogen receptors (ER) (ER alpha, ER beta)
and progesterone receptors (PR) (PR-A and PR-B) were
performed and analysed as previously published by our
research group [25] (Continued)
Chemotherapy (%) (n = 292) Yes 7 (2.4)
No 283 (96.9)
Declined 2 (0.7)
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logical evaluation including tumour staging and grading
were performed by an experienced gynaecologic path-
ologist (D.M.) according to the criteria of the Inter-
national Federation of Gynaecologists and Obstetricians
(FIGO) and the World Health Organization (WHO).
Study design
Tissue samples of endometrial cancer tissue gained at
surgery at the Department of Obstetrics and Gynaecol-
ogy of the Ludwig-Maximilians University Munich be-
tween 1990 and 2001 were randomly retrieved from the
archive. FFPE material was stained for Gd, GdA or
underwent ISH for Gd mRNA; clinical data were ana-
lysed retrospectively. Patients with uterine sarcoma were
excluded from the study. Patient’s clinical data (Table 1)
were available from patient charts, aftercare files and
tumour registry database information. Mean follow-up
time was 13.8 years (95% CI: 13.1-14.5) with 160 deaths.
Mean overall survival was 13.6 years (95% CI: 12.6-14.6).
The outcome assessed was patient survival.
The study has been approved by the ethics committee
of the Ludwig-Maximilians University Munich (approval
number: 063–13) and has been carried out in compli-
ance with the guidelines of the Helsinki Declaration of
1975.
Statistical analysis methods
Statistical analysis was performed using SPSS 20.0 (PASW
Statistic, Ehningen, Germany). The non-parametric Kruskal-
Wallis rank-sum test and for pairwise comparisons the
non-parametric Mann–Whitney-U rank-sum test were
used to test for differences between groups. Correlation
analysis was performed using Spearman correlation. For
the comparison of survival times, Kaplan-Meier curves
were drawn. The chi-square statistic of the log-rank test
was calculated to test differences between survival curves
for significance. Multivariate analysis for prognostic value
was performed using the Cox-regression model. Mean
values are displayed ± standard error and p values below
0.05 were considered statistically significant.
Immunohistochemical staining was assessed using a
semiquantitative immunoreactive score (IRS) according
to Remmele and Stegener [35]. The IRS, ranging from 0
Table 2 Immunohistochemistry: Antibodies detecting Gd or GdA were published by Jeschke et al. 2006 [26] and
Jeschke et al. 2005 [32], respectively
Antibody Host/clonality Epitope retrieval Blocking Dilution/incubation Negative control Reaction system
Gd [32] Rabbit/
polyclonal
Not performed Reagent 1
(5 min)









(5 min, pressure cooker)
1.5% horse
serum (20 min)




Vectastain elite (mouse IgG)
kit (Burlingame, CA)
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1 = weak, 2 =moderate, and 3 = strong staining) and the
percentage of positively stained cells (0 = no, 1 ≤ 10%, 2 =
11–50%, 3 = 51–80% and 4 ≥ 81% cells). The slides were
reviewed in a blinded fashion by two independent ob-
servers. Intermediate positivity was set as median IRS ±
one IRS unit, while low to negative immunoreactivity was
assumed for IRS ≤median IRS - two IRS units and high
positivity was attributed for IRS ≥median IRS + two IRS
units (Additional file 2).
Gd mRNA expression was analysed automatically in a
computer aided procedure as published previously by
our group [27,28,34]. Briefly, five digital pictures were
taken randomly from each tissue section (3CCD color
camera, HV-C20M, Hitachi, Denshi, Japan, and Axiolab,
Carl Zeiss, Jena, Germany). Optical density of white
background colour was attuned to 250 to standardize
measurements. Mean optical density and Gd positive
pixels were determined by KSRun software (imaging sys-
tem KS400, release 3.0, Zeiss). In accordance to the IRS
system Gd positive pixels were ranked in nine groups
representing lowest (group 1) to highest (group 9) Gd
mRNA expression.
Results
Endometrial cancer tissue of 292 patients (Table 1) was
available. Data of 291 cases analysed for Gd, 289 cases
stained for GdA and 254 cases analysed for Gd mRNA
were included in the statistical analysis. Remaining cases
(IHC: Gd: n = 1, GdA: n = 3 and ISH: Gd mRNA: n = 38)
had to be excluded due to technical reasons. Mean pa-
tient age at primary diagnosis was 65.1 ± 0.6 years (range
35–88 years) and further patient characteristics are listed
in Table 1.
Gd mRNA expression in endometrial cancer tissue
Intermediate (37.8%) or high (24.0%) expression of Gd
mRNA (PAEP, progestagen-associated endometrial pro-
tein) was detected in the majority of cases investigated
here (Figure 1). Though mRNA in situ hybridization re-
vealed Gd transcripts to predominantly localize to the
tumour epithelium, no significant difference in Gd mRNA
expression was detected among histological tumour sub-
types (Figure 1). In the current study positivity for Gd
mRNA was neither statistically associated with histological
tumour grade nor with the patients’ FIGO stage.Gd and GdA in endometrial cancer tissue
Using a polyclonal antiserum we also proofed presence
of Gd protein in endometrial tissue. Immunohistochemi-
cal staining showed endometrial cancer tissue to be
intermediately or highly positive for Gd in 52.2% or
20.6% (Figure 2, Table 1), respectively. A significant pro-
portion of endometrioid carcinoma cases were observed
to produce an immunosuppressive Gd glyocmodifica-
tion, termed GdA. The latter was present at intermediate
or high levels in 62.6% or 9.0% of cases, respectively.
Inspite the fact that immunoreactivity for the Gd protein
was positively correlated with Gd mRNA expression
(Correlation coefficient 0.155, p = 0.013), no such associ-
ation was observed when Gd mRNA was correlated with
the glyco-variant GdA. However, GdA immunoreactivity
was closely correlated with Gd protein expression (Cor-
relation coefficient 0.249, p < 0.001).
The highest median Gd expression was noted for the
undifferentiated histological subtype (median IRS 8.0;
mean IRS 7.80 ± 0.49, Additional file 3), followed by the
endometrioid (median IRS 6.0; mean IRS 5.9 ± 0.23),
the serous (median IRS 6.0; mean IRS 5.74 ± 0.76) and the
mixed cell type (median IRS 6.0; mean IRS 4.97 ± 0.60),
though differences among Gd expression and the histo-
logical subtypes did not reach statistical significance (p >
0.05) (Figures 2 and 3). Comparable results were observed
for GdA expression and the histological subtype (Figure 2
and 3). The most common histological subtypes (endome-
trioid and serous) show median GdA expression of IRS
6.0. Also, no statistically significant differences in GdA ex-
pression were observed among the different histological
subtypes (p > 0.05) (Figures 2, 3 and Additional file 3).
Interestingly, there is a significant reduction in Gd ex-
pression observed from FIGO III to FIGO IV (p = 0.044)
(Figure 3). However, overall Gd/GdA immunoreactivities
comparing cases of low vs. high FIGO stage were not
significantly different (Additional file 4). There were no
significant differences in Gd and GdA expression be-
tween different tumour grades (Figure 3). Immunoreac-
tivity of Gd or GdA staining was not significantly
different comparing cases being negative vs. positive for
ERs, PRs or co-morbidities.
Prognostic value
Statistical analysis was also performed to test for a prog-
nostic value of Gd or GdA expression. Univariate Kaplan
Figure 1 Gd mRNA (PAEP) was detected in endometrial cancer tissue by in situ hybridization. Representative microphotographs of
Glycodelin (Gd) mRNA (PAEP, progestagen-associated endometrial protein) as detected by in situ hybridization in different histological subtypes
(A-C) of endometrial cancer tissue are shown. Samples were treated with an antisense riboprobe recognizing Gd mRNA (A-C) or with the
complementary sense riboprobe as a negative control (insert in A), respectively. Mean optical density of Gd mRNA signal has been quantified in a
semi-automated manner and Gd positive pixels were determined by KSRun software. Gd mRNA positivity in dependence of histological subtype
(D), FIGO stage (E) and grading (F) is illustrated using box plot diagrams. Scale bar in C represents 100 μm and refers to A-C.
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and high Gd expression (p = 0.039) (Figure 4A). In con-
trast, highly positive GdA endometrial cancer patients had
a poor outcome compared to intermediate and low GdA
expression (p = 0.003) (Figure 4B). Gd mRNA expression
was not significantly associated with patients’ outcome.
Besides tumour stage, grade and the concomitant diag-
nosis of hypertension (each p < 0.05), Cox-regression
analysis (Table 3) showed GdA to be an independent
prognostic marker for patient survival (p = 0.002, 95% CI
1.362-3.943).Figure 2 Glycodelin and Glycodelin A protein was detected in endom
microphotographs of Glycodelin (Gd, A-C) and its immunosuppressice glyco-
different histological subtypes of endometrial cancer tissue are shown. Pan-G
found to be predominantly produced by epithelial components of endometrDiscussion
Endometrial cancer can be subdivided into two histo-
logical subtypes, the estrogen-associated Type I and the
estrogen-independent Type II carcinoma [36,37]. The
most common cause for endometrial Type I carcinoma
is thought to be an excess of estrogens, which are inad-
equately antagonized by gestagens [38]. Therefore obes-
ity, polycystic ovarian syndrome, menopausal hormone
use are associated with a higher risk for endometrial
cancer [3-5]. The Type II carcinoma, which comprises
mostly the serous and clear cell histological subtypes, isetrial cancer tissue by immunohistochemistry. Representative
variant Glycodelin A (GdA, D-F) as detected by immunohistochemistry in
lycodelin as well as its immunosuppressive glyco-variant Glycodelin A was
ial carcinomas. Scale bars in F represent 100 μm and refer to A-F.
Figure 3 Glycodelin as well as its immunosuppressive glyco-variant Glycodelin A protein was analysed and quantified in endometrial
cancer tissue. Quantification of Glycodelin (Gd; A, C, E) and its immunosuppressive glyco-variant Glycodelin A (GdA; B, D, F) by immunohisto-
chemistry is shown. Gd/GdA was visualized in endometrial carcinoma tissue of different histological subtypes (A, B), FIGO stages (C, D) or tumour
grades (E, F). Gd and GdA were detected by immuno-histochemistry and quantified employing an immunoreactive score (IRS) ranging from 0
(lowest) to 12 (highest). Significant differences (p < 0.05) as determined by Mann–Whitney Test are indicated by #.
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survival. In contrast to endometrial Type I carcinomas
estrogen dominance does not seem to be causally linked
to this type of the disease, rather higher age and previ-
ous radiation therapy of the uterus [39].Figure 4 Kaplan Meier survival analyses were performed for Glycodel
of patients with low, intermediate and high Glycodelin A (A) and GlycodelinThe majority of cases are classified as Type I carcinoma
and comprise the endometrioid adenocarcinomas. In lit-
erature it accounts for 75-85% of all adenocarcinomas
[36,37,40], which is in accordance with our study popula-
tion of 72.6% endometrioid tumours.in and Glycodelin A in endometrial cancer patients. Overall survival
(B) protein expression as detected by immunohistochemistry is shown.
Table 3 Multivariate COX regression analysis: Patient survival was analysed by multivariate COX regression analysis
95% CI
Covariate Coefficient (bi) [HR Exp(bi)] Lower Upper P-value
FIGO stage <0.001
I (0.000) (1.00)
II −3.064 .047 .011 .192 <0.001
III −3.025 .049 .010 .233 <0.001
IV −1.810 .164 .040 .669 .012
WHO grade .023
1 (0.000) (1.00)
2 −.820 .440 .246 .790 .006
3 −.561 .571 .325 1.002 .051
Histology 0.068
Endometrioid (0.000) (1.00)
Serous −.297 .743 .233 2.372 .616
Clear cell −.069 .934 .260 3.349 .916
Mucinous −1.423 .241 .024 2.403 .225
Squamous cell .074 1.077 .260 4.470 .918
Mixed cell 3.167 23.742 2.245 251.079 .008
Undifferentiated −.163 .850 .255 2.828 .790
Lymph node metastasis −.732 .481 .209 1.109 .086
Age (≤50 y vs. >50 y) 1.939 6.953 .909 53.204 .062
Diabetes .451 1.570 .880 2.800 .127
Obesity −.065 .937 .600 1.462 .774
Hypertension .454 1.575 1.043 2.380 .031
Lymphangiosis .216 1.241 .631 2.443 .532
Hemangiosis .681 1.975 .476 8.187 .348
ER alpha −.031 .970 .652 1.442 .880
PRA −.156 .855 .572 1.279 .446
GdA .840 2.317 1.362 3.943 .002
Gd −.298 .743 .456 1.209 .232
Significant results are shown in bold.
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hypertension to be a negative predictor in patients diag-
nosed with endometrial cancer. This finding is in ac-
cordance with newly published data by Nicholas et al.,
who reported diabetes and hypertension to adversely
affect survival and demanded to give more attention to
comorbidities, since they are gaining more influence on
current health care and policy [41].
Though Gd has been identified in a range of different
tissue types, not all of them do indeed synthesize the pro-
tein, which is made evident by the presence and absence
of Gd mRNA [14,15,42,43]. Our immunhistochemistry
results were confirmed by in situ hybridization showing
not only the presence of Gd in endometrial cancer but
also its synthesis and thus underline its role in carcino-
genesis. To our best knowledge this is the first studyreporting Gd to be present on both mRNA and protein
level in endometrial cancer. Moreover, existence of Gd
mRNA and its close correlation to Gd protein immuno-
reactivity suggests that endometrial cancer cells them-
selves possess the ability to synthesize the Gd protein.
Interestingly, no significant association of Gd mRNA and
the immunosuppressive Gd glyo-epitope GdA was ob-
served, implying that GdA positivity marks a subfraction
of endometrioid cancer that cannot be predicted by sole
presence of Gd mRNA. Unfortunately, due to the very
limited amount of tissue available protein extraction and
western blot analysis, which would allow direct quantifi-
cation of Gd/GdA of the same sample, was not possible.
In hormone-dependent tumours, Gd has been described
to have various effects through reduced expression of
oncogens and raised expression of tumour suppressor
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tumour growth, decreased metastatic properties or de-
creased chemoresistance [24,44]. Hautala et al. showed
glycodelin to reduce breast cancer tumour growth in vivo
[44]. Koistinen et al. transfected endometrial adenocarcin-
oma HEC-1B cells with Gd cDNA in both antisense and
sense orientations [24]. They observed sense-transfected,
Gd-producing carcinoma cells to have a reduced prolifera-
tion, morphologic changes, and altered expression of
cancer-related genes in comparison to native and
antisense-transfected carcinoma cells [24]. These results
illustrate some aspects of Gd’s potential in gynecolocical
cancers. In some hormone-depending tumours, Gd ex-
pression has been shown to go along with a favourable
outcome, like in breast and ovarian cancer [45,46]. Results
on ductal carcinoma in situ and invasive breast revealed
that Gd positivity is inversely correlated with the occur-
rence of metastasis [45]. These data are in line with our
findings, though Gd expression reached only univariate
prognostice significance in Kaplan Meier analysis.
Recently histone deacetylase inhibitors (HDACIs) have
been highlighted as promising new anti-cancer agents.
In 2006 the HDACI suberoylanilide hydroxamic acid
(SAHA, Vorinostat (rINN), Zolinza®) has been approved
by the FDA for the treatment of cutaneous T-cell lymph-
oma and has further been evaluated in patients suffering
from e.g. glioblastoma multiforme [47], non-small-cell
lung [48] cancer or myelodysplastic syndroms [49].
Uchida et al. [50-52] demonstrated that SAHA is capable
of up-regulating Gd in endometrial cancer and chorio-
carcinoma cell lines and further that SAHA induced Gd
in fact influences cell differentiation and migration in
the model system employed. Since we found that Gd is
significantly associated with prolonged overall survival in
endometrial cancer, it remains challenging to investigate
whether endometrial cancer patients might also benefit
from the application of SAHA. Of course randomized
and properly powered clinical trials are indispensable in
order to validate this hypothesis on a clinical basis.
Depending on Gd glycosylation status, it can induce
apoptosis in T cells and monocytes. These in vivo results
on Gd and GdA may explain the partially contradictory
results in clinical studies. In contrast to Gd, we observed a
poor outcome in patients expressing the immunosuppres-
sive isoform GdA. This result was made not only on the
basis of univariate but also multivariate survival analysis
and is in concordance with a recently published study on
ovarian cancer and GdA, where we report GdA to be a
prognostic marker for poor outcome in advanced stage
ovarian cancer [23]. Nevertheless, there are controversial
results on Gd expression and patient survival [23,45,46,53].
These may be attributable to various mono- and polyclonal
antibodies being either peptide-specific or glycosylation
specific. Bearing in mind that differently glycosylated Gdisoforms may exert opposing actions may at least partially
explain the conflicting research results published on this
issue [54]. Functional analysis e.g. employing an endomet-
rial cancer animal model is thus needed to further clarify
the immunomodulatory actions of Gd/GdA.Conclusion
In conclusion, Gd and GdA are commonly expressed in
endometrial cancer tissue and seem to be of relevance in
tumourigenesis. They differ not only in glycosylation but
also in their biological activity, since Gd is associated with
a better survival, whereas GdA holds prognostic signifi-
cance for a poor outcome in endometrial cancer patients.
Therefore, Gd and especially GdA might help to select pa-
tients for a more individualized tumour therapy.Consent
As stated above the current study has been approved by
the ethics committee of the Ludwig-Maximilians Univer-
sity Munich (approval number: 063–13) and has been
carried out in compliance with the guidelines of the
Helsinki Declaration of 1975. All specimens included in
this study were left over samples collected during rou-
tine clinical diagnostics. Patient data were fully anon-
ymised and the current study has been approved by the
ethics committee of the LMU Munich.Additional files
Additional file 1: Representative microphotographs of positive (A, B)
and negative controls (C, D) for Gd (A, C) and GdA (B, D) are shown.
Placental tissue was either incubated with the respective antibodies
detecting Gd (A) or GdA (B) or with the respective species matched pre-
immune sera (C, D). Scale bar in A equals 100 μm and applies to A-D.
Additional file 2: Representative microphotographs of Gd (A, C)
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